Skip to content

EVDW

Active Private limited companyfounded 2016active for 10 yearsBloemstraat 32, 9050 GhentKBO/BCE: BE 0659.858.336

Lifetime

9 annual accounts with figures on one time axis
peak of €99,920 in 2017
€43,899▼ 0.4%
peak of €220,802 in 2017
€72,869▲ 8.5%
peak of €814,592 in 2025
€814,592▲ 9.8%
€563,425▼ 12.2%
Board1 name since 2016
1 director
Documentsfilings and deeds
31-08-202631 days late
2025abbreviated format
The year was quiet, with no large shift from the year before.

Key points

from the 2025 annual accounts

Equity

€814,592 ▲ 9.8%

EVDW has made a profit in every financial year since 2017.

Turnover

≈ €200,000 estimated

The accounts state no turnover.

Filings

9 annual accounts 8 late
AprilJune31 JulyOctober20202025

The 2019 accounts came in latest, 41 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • all the sharesdeed of 07-11-2023

Shares in 1 company,

Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0659858336
appointed as director holds all the shares · General meeting of 23-10-2023 · Gazette deed
Incorporation Founding capital of €18,600, 100 shares · Founded by · appointed as manager · published on 04-08-2016 · Gazette deed
First establishment EVDW BVBA, Bloemstraat 32, Ghent
All 16 events

Comparable companies

same main activity, similar in size and age
Company
EVDW Ghent €1.4m €43,899 59.1% -
RED ONE PHARMA Brussels €1.2m €38,836 43.2% -
Mipharma Deerlijk €1.4m €58,706 19.5% -
ASVAPO Kortrijk €1.2m €54,529 20.3% -
BPHARMA Gerpinnes €1.2m €35,795 43.2% -
SIMON IMMO Ecaussinnes €2.0m €32,649 30.5% -
SAARBACH DINO Chaudfontaine €1.4m €74,530 78.0% 0

These companies have the same main activity as EVDW: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.2m and €2m, founded between 2012 and 2018.

Official details

Source: KBO
Status
Active since 18-07-2016Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.256.579.6909050 Ghent, since 18-07-2016
Financial year end
31 December
Peppol
Reachable since 21-10-2026
Company details

Annual accounts 2025

€1.4m▼ 0.4%
Filing
Filed on 31-08-2026
Financials

Insights on EVDW

EVDW files the abbreviated format. That format states no turnover. The gross margin fell from €99,920 in 2017 to €43,899 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about EVDW

What is the company number of EVDW?
The company number of EVDW is 0659.858.336. The VAT number is the same number with BE in front: BE 0659.858.336.
Where is EVDW based?
The registered office is at Bloemstraat 32, 9050 Ghent.Company details
What does EVDW do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of EVDW?
EVDW is a private limited company (BV).
When was EVDW founded?
EVDW was founded on 18-07-2016.
Is EVDW still active?
Yes, EVDW is an active enterprise in the KBO register.
What is the turnover of EVDW?
The turnover in financial year 2025 is about €200,000. This figure is estimated from the gross margin of €43,899 and 71 comparable companies (NACE 477). It probably lies between €110,000 and €370,000.Financials
Is EVDW profitable?
In financial year 2025, EVDW made a profit of €72,869.
Where can I find the annual accounts of EVDW?
EVDW filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of EVDW due?
EVDW must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.